Metastatic Gastric Adenocarcinoma Active Not Recruiting Phase 2 Trials for Irinotecan (DB00762)

Also known as: Adenocarcinoma gastric / Adenocarcinoma of stomach (disorder)

IndicationStatusPhase
DBCOND0074521 (Metastatic Gastric Adenocarcinoma)Active Not Recruiting2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT03641313Berzosertib and Irinotecan in Treating Patients With Progressive, Metastatic, or Unresectable TP53 Mutant Gastric or Gastroesophageal Junction CancerTreatment